Invention Grant
- Patent Title: CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells
-
Application No.: US16374026Application Date: 2019-04-03
-
Publication No.: US11266624B2Publication Date: 2022-03-08
- Inventor: Weimin Gao
- Applicant: Texas Tech University System
- Applicant Address: US TX Lubbock
- Assignee: Texas Tech University System
- Current Assignee: Texas Tech University System
- Current Assignee Address: US TX Lubbock
- Agency: Chalker Flores, LLP
- Agent Edwin S. Flores; Daniel J. Chalker
- Main IPC: A61K31/366
- IPC: A61K31/366 ; A61K31/519 ; A61K31/5377 ; A61K31/517 ; A61P35/00 ; A61K31/4439 ; A61K31/4245 ; A61K31/506 ; A61K31/4196 ; A61K31/4412
Abstract:
The present invention includes a method and compositions for preventing primary or acquired resistance of epidermal growth factor receptors (EGFR) inhibitors in a cancer with deregulated EGFR comprising: identifying a subject suspected of needing treatment for primary or acquired resistance to epidermal growth factor receptor (EGFR) inhibitors of the cancer with deregulated EGFR; and providing the subject with a therapeutically effective amount of a chromosome region maintenance 1 (CRM1) inhibitor and an inhibitor of EGFR in an amount sufficient to reduce or eliminate the cancer.
Public/Granted literature
- US20190298687A1 CRM1 INHIBITORS REDUCE PRIMARY AND ACQUIRED RESISTANCE OF EGFR INHIBITORS IN LUNG CANCER CELLS Public/Granted day:2019-10-03
Information query
